Ispronicline (AZD-3480): A Comprehensive Review of a Selective α4β2 Nicotinic Receptor Agonist from Clinical Promise to Discontinuation

Compound Identification and Physicochemical Properties

Ispronicline is an investigational small molecule drug developed for the treatment of cognitive and neurological disorders.[1][ Throughout its development, it has been referred to by several names and codes, which are essential for navigating the scientific and clinical literature. A comprehensive understanding of its identity and chemical properties provides the foundation for interpreting its pharmacological and clinical profile.]

Nomenclature and Regulatory Identifiers

The compound was assigned the International Nonproprietary Name (INN) and United States Adopted Name (USAN) of Ispronicline.[1] During its preclinical and clinical development phases, it was known by several developmental codes, most prominently TC-1734 (by Targacept), AZD-3480 (by AstraZeneca), and RJR-1734 (by R.J. Reynolds).[2] The IUPAC nomenclature for the molecule is (2S,4E)-5-(5-isopropoxypyridin-3-yl)-N-methylpent-4-en-2-amine, with minor variations such as (E,2S)-N-methyl-5-(5-propan-2-yloxy-3-pyridinyl)pent-4-en-2-amine also appearing in chemical databases.[2][ For unambiguous identification, a set of regulatory and database identifiers has been assigned, which are consolidated in Table 1.]

Chemical Structure and Properties